Novartis loses patent battle in India: Time to realign the business model to emerging markets?

On April 1, 2013, the Supreme Court of India rejected Novartis’ patent application for its cancer treatment drug, Glivec. Novartis had applied for patent protection in 2006, and after a seven-year legal battle, it all ended in disappointment for the Swiss pharmaceutical company. Public opinion seeme...

Full description

Saved in:
Bibliographic Details
Main Authors: REDDY, Srinivas K., LLEWELYN, David, MATHUR, Sarita
Format: text
Language:English
Published: Institutional Knowledge at Singapore Management University 2013
Subjects:
IP
Online Access:https://ink.library.smu.edu.sg/cases_coll_all/54
https://cmp.smu.edu.sg/case/2601
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Singapore Management University
Language: English
id sg-smu-ink.cases_coll_all-1050
record_format dspace
spelling sg-smu-ink.cases_coll_all-10502024-09-10T03:04:27Z Novartis loses patent battle in India: Time to realign the business model to emerging markets? REDDY, Srinivas K. LLEWELYN, David MATHUR, Sarita On April 1, 2013, the Supreme Court of India rejected Novartis’ patent application for its cancer treatment drug, Glivec. Novartis had applied for patent protection in 2006, and after a seven-year legal battle, it all ended in disappointment for the Swiss pharmaceutical company. Public opinion seemed to overwhelmingly support the Supreme Court’s decision - legal counsel, politicians, public health advocates and heads of generic drug manufacturers - all shared the opinion that Indians should rightfully have access to cheaper generic alternatives for lifesaving drugs and that multinational pharmaceutical companies should not be allowed to benefit from “evergreening” – that is, making minor improvements to existing drugs and prolonging the patent life. However, drug companies often spent decades and invested billions of dollars to develop a single drug. These companies expected a reasonable return for the investments and risks that they had taken. If their innovations were not protected from generics in developing countries like India, what incentives would pharmaceuticals companies have to market their life-saving drugs in these countries? However, this side of the debate seemed to have been drowned in the sea of idealistic and nationalistic sentiments. The patent protection available in the United States, Western Europe and Japan had made the existing business models and pricing strategies viable and effective for decades. Yet these now needed to be re-evaluated for emerging markets such as India; taking into account affordability, limited access to health insurance and government safety nets, different marketing and distribution networks, and the powerful generics lobby. So what should Novartis’ strategy be in India, and for emerging markets, in general? The company needed to redefine its business model and consider alternative pricing, marketing and distribution strategies if it hoped to expand its footprint in one of the fastest growing pharmaceutical markets in the world. 2013-08-01T07:00:00Z text application/pdf https://ink.library.smu.edu.sg/cases_coll_all/54 https://cmp.smu.edu.sg/case/2601 Case Collection eng Institutional Knowledge at Singapore Management University Pharmaceuticals Intellectual Property IP Emerging Markets Novartis Glivek Drugs Business Models Ethics Patenting Big Pharma Business Model Adaptation Pricing Pricing Strategies Business Administration, Management, and Operations Business Law, Public Responsibility, and Ethics International Business Marketing
institution Singapore Management University
building SMU Libraries
continent Asia
country Singapore
Singapore
content_provider SMU Libraries
collection InK@SMU
language English
topic Pharmaceuticals
Intellectual Property
IP
Emerging Markets
Novartis
Glivek
Drugs
Business Models
Ethics
Patenting
Big Pharma
Business Model Adaptation
Pricing
Pricing Strategies
Business Administration, Management, and Operations
Business Law, Public Responsibility, and Ethics
International Business
Marketing
spellingShingle Pharmaceuticals
Intellectual Property
IP
Emerging Markets
Novartis
Glivek
Drugs
Business Models
Ethics
Patenting
Big Pharma
Business Model Adaptation
Pricing
Pricing Strategies
Business Administration, Management, and Operations
Business Law, Public Responsibility, and Ethics
International Business
Marketing
REDDY, Srinivas K.
LLEWELYN, David
MATHUR, Sarita
Novartis loses patent battle in India: Time to realign the business model to emerging markets?
description On April 1, 2013, the Supreme Court of India rejected Novartis’ patent application for its cancer treatment drug, Glivec. Novartis had applied for patent protection in 2006, and after a seven-year legal battle, it all ended in disappointment for the Swiss pharmaceutical company. Public opinion seemed to overwhelmingly support the Supreme Court’s decision - legal counsel, politicians, public health advocates and heads of generic drug manufacturers - all shared the opinion that Indians should rightfully have access to cheaper generic alternatives for lifesaving drugs and that multinational pharmaceutical companies should not be allowed to benefit from “evergreening” – that is, making minor improvements to existing drugs and prolonging the patent life. However, drug companies often spent decades and invested billions of dollars to develop a single drug. These companies expected a reasonable return for the investments and risks that they had taken. If their innovations were not protected from generics in developing countries like India, what incentives would pharmaceuticals companies have to market their life-saving drugs in these countries? However, this side of the debate seemed to have been drowned in the sea of idealistic and nationalistic sentiments. The patent protection available in the United States, Western Europe and Japan had made the existing business models and pricing strategies viable and effective for decades. Yet these now needed to be re-evaluated for emerging markets such as India; taking into account affordability, limited access to health insurance and government safety nets, different marketing and distribution networks, and the powerful generics lobby. So what should Novartis’ strategy be in India, and for emerging markets, in general? The company needed to redefine its business model and consider alternative pricing, marketing and distribution strategies if it hoped to expand its footprint in one of the fastest growing pharmaceutical markets in the world.
format text
author REDDY, Srinivas K.
LLEWELYN, David
MATHUR, Sarita
author_facet REDDY, Srinivas K.
LLEWELYN, David
MATHUR, Sarita
author_sort REDDY, Srinivas K.
title Novartis loses patent battle in India: Time to realign the business model to emerging markets?
title_short Novartis loses patent battle in India: Time to realign the business model to emerging markets?
title_full Novartis loses patent battle in India: Time to realign the business model to emerging markets?
title_fullStr Novartis loses patent battle in India: Time to realign the business model to emerging markets?
title_full_unstemmed Novartis loses patent battle in India: Time to realign the business model to emerging markets?
title_sort novartis loses patent battle in india: time to realign the business model to emerging markets?
publisher Institutional Knowledge at Singapore Management University
publishDate 2013
url https://ink.library.smu.edu.sg/cases_coll_all/54
https://cmp.smu.edu.sg/case/2601
_version_ 1814047860142899200